Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of emicizumab prophylaxis versus no prophylaxis in hemophilia A
CTR20180012Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (4 arms), sponsored by Roche. Primary endpoint: Bleeding frequency over time (bleeding rate). Started Apr 2018; status: active.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20180012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180012.